Pancreatic cancer organoids recapitulate disease and allow personalized drug screening

We report derivation of 30 Patient-Derived Organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical for pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic. The PRMT5 inhibitor EZP015556, shown to target MTAP negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP+ tumors. Taken together, the work presented here provides a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs.

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

3 Datasets 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001004528	This dataset contains 31 pancreatic organoid samples used in the 'organoid data of pancreatic cancers ' study	HiSeq X Ten	31
EGAD00001004529	This dataset contains 53 blood samples used as controls in study EGAXXXXX and EGAXXXXX	HiSeq X Ten	53
EGAD00001005217	RNA sequencing of 31 pancreatic cancer organiods	NextSeq 500	31

Publications	Citations
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Driehuis E, van Hoeck A, Moore K, Kolders S, Francies HE, Gulersonmez MC, Stigter ECA, Burgering B, Geurts V, Gracanin A, Bounova G, Morsink FH, Vries R, Boj S, van Es J, Offerhaus GJA, Kranenburg O, Garnett MJ, Wessels L, Cuppen E, Brosens LAA, Clevers H. Proc Natl Acad Sci U S A 116: 2019 26580-26590	190